摘要
目的：检测胃癌患者血清中长链非编码RNA（ lncRNA） BC200表达水平，分析其与患者临床特征的关系，探讨其在胃癌诊断中的价值。方法病例对照研究。采用实时荧光定量聚合酶链反应方法对2014年11月至2015年7月山东大学齐鲁医院收治的124例胃癌患者、41例萎缩型胃炎患者、59名健康体检者血清中的lncRNA BC200的表达水平进行检测。同时采用电化学发光免疫分析法检测血清中癌胚抗原（CEA）、糖类抗原72－4（CA72－4）。对31例成功接受胃癌根治术的患者手术前及术后3、7、10、30和100 d血清 lncRNA BC200水平进行动态监测。应用ROC 曲线分析lncRNA BC200、CEA及CA72－4诊断胃癌的敏感度和特异度。两组间比较采用Mann－Whitney U检验，多组间比较采用Kruskal－Wallis H检验。结果胃癌患者血清BC200表达水平Ⅰ＋Ⅱ期组[1．041（0．794，1．462）]及Ⅲ＋Ⅳ期组[1．290（0．978，1．794）]较癌前病变组[0．969（0．699，1．219）]、健康对照组[0．801（0．556，1．599）]有明显升高（H＝54．68，P＜0．0001）；与术前[1．120（0．859，1．663）]相比，胃癌患者血清lncRNA BC200表达水平在术后10 d[0．903（0．724，1．182）]（U＝55．0，P＜0．0001）、30 d[0．759（0．671，1．037）]（U＝299．0，P＝0．0261）、100 d[0．478（0．378，0．635）]（U＝41．0，P＜0．0001）均有显著降低。血清lncRNA BC200诊断胃癌的曲线下面积（ AUC）为0．865，高于CA72－4（ AUC＝0．699）及 CEA （ AUC ＝0．807）。三者联合检测 AUC 为0．934。结论胃癌患者血清中lncRNA BC200表达水平明显升高，lncRNA BC200有望作为胃癌诊断及疗效监测的潜在生物标志物。（中华检验医学杂志，2017，40：138－142）
Objective To detect serum level of long noncoding RNA （ lncRNA） BC200 in gastric cancer（GC） patients, and investigate its relationship with clinical features , and evaluate its diagnostic value for GC.Methods A case-control study was performed.From November 2014 to July 2015, serum levels of lncRNA BC200 were detected by real-time quantitative polymerase chain reaction in 124 patients with GC , 41 patients with atrophic gastritis and 59 normal controls who were hospitalized in Qilu Hospital of Shandong University.Meanwhile , serum carcinoembryonic antigen （ CEA ） and carbohydrate antigen 72-4 （ CA72-4 ） were detected by electrochemical luminescence immunoassay .Serum levels of lncRNA BC200, before and 3, 7, 10, 30, 100 days after radical operation in another 31 patients with GC were determined.The sensitivity and specificity of serum lncRNA BC200, CEA and CA72-4 were analyzed by using of the receiver operating characteristic （ ROC） curve.The comparison between two groups was performed with Mann-Whitney U test and the comparison among many groups was conducted with Kruskal-Wallis H test.Results Serum levels of lncRNA BC200 in GC patients with stage Ⅰ and Ⅱ[1.041（0.794,1.462）] and stage Ⅲ and Ⅳ[1.290＆amp;nbsp;（0.978,1.794）]were significantly higher than those in patients with precancerous lesion [0.969（0.699, 1.219）]and normal controls[0.801（0.556,1.599）]（H =54.68,P〈0.000 1）.Compared with pre-operation[1.120 （0.859,1.663）], the serum BC200 levels decreased significantly in 10 days [0.903 （0.724,1.182）]（U=55.0,P〈0.000 1）, 30 days[0.759（0.671,1.037）]（U=299.0,P=0.026 1）, and 100 days[0.478（0.378,0.635）]（U=41.0,P〈0.000 1） after surgery.The area under the receiver operating characteristics curve （ AUC） of serum lncRNA BC200 was 0.865 for GC diagnosis, which was significantly higher than that of serum CA 72-4 （ AUC =0.699 ） or CEA （ AUC =0.807 ） .The AUC of combined detection of three tests was 0.934.Conclusion Serum lncRNA BC200 levels are significantly increased in GC patients , which may be used as a potential biomarker in GC diagnosis and monitoring .
出处
《中华检验医学杂志》
CAS
CSCD
北大核心
2017年第2期138-142,共5页
Chinese Journal of Laboratory Medicine
基金
山东大学齐鲁医院科研基金及山东大学基本科研业务专项资金（2015QLMS47）
作者简介
通信作者：张义，电子信箱：zhangyi-3144@163．com
